Pfizer/BI Spiriva
Executive Summary
Once-daily chronic obstructive pulmonary disease NDA filing expected in 2001. Boehringer Ingelheim's Spiriva will be Pfizer's next co-promotion project, firms announce April 11. The inhaled bronchodilator tiotropium will be Pfizer's first COPD drug; the company has an endothelin antagonist in Phase II for the indication